Dr Reddy’s Laboratories announced that it has partnered with Alvotech, to co-develop, manufacture, and sell a biosimilar version of Keytruda (pembrolizumab), for global markets.

EQS-News: Formycon AG / Key word (s): Regulatory Approval Lucentis® biosimilar FYB201/Ranivisio® (ranibizumab) approved in Brazil 05.06.2025 / 06:30 CET/CEST The issuer is solely responsible for the ...

Dr. Reddy’s Laboratories RDY announced that it has entered into a collaboration and license agreement with Alvotech ALVO to co-develop and commercialize a biosimilar candidate to Merck ’s MRK ...

Dr. Reddy’s, Alvotech to co-develop, market biosimilar of Merck’s cancer drug Keytruda Worldwide sales of Keytruda in 2024 were $29.5 billion Updated - June 05, 2025 02:46 pm IST - HYDERABAD ...

As our data shows, on average, patients paid more than four times as much out of pocket per month for Humira compared to Hadlima,” said Jon Martin, U.S. commercial lead, biosimilars and ...

Serve You Rx, a pharmacy benefit manager, has added two recently approved biosimilars to Stelara to its formulary, the company announced Thursday. Milwaukee, Wisconsin-based Serve You Rx is an ...

It’s important that the biosimilar market continue to build on the success established last year in 2021. In 2020, we saw seven of the 20 biosimilars currently available in the US launch.

Keytruda posted global sales of $29.5 billion in 2024, making it a major target for biosimilar development. Alvotech and Dr. Reddy's will share development, manufacturing, and commercialization ...

In 2024, we launched our first biosimilar in the United Kingdom, Versavo® (biosimilar bevacizumab). This follows our launch of pegfilgrastim in the U.S and Europe through our partner.